The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread.

Publication Type:

Journal Article


Cancer research, Volume 68, Issue 6, p.1768-76 (2008)


2008, Animals, Center-Authored Paper, Cerebellar Neoplasms, Clinical Research Division, Comparative Medicine Core Facility, Disease Models, Animal, Experimental Histopathology Core Facility, Hedgehog Proteins, Medulloblastoma, Meningeal Neoplasms, MICE, Mice, Inbred C57BL, Mice, Nude, Mice, Transgenic, Receptors, G-Protein-Coupled, Scientific Imaging Core Facility, Shared Resources, Transgenes, Translational Bioimaging Center Core Facility


Toward the goal of generating a mouse medulloblastoma model with increased tumor incidence, we developed a homozygous version of our ND2:SmoA1 model. Medulloblastomas form in 94% of homozygous Smo/Smo mice by 2 months of age. Tumor formation is, thus, predictable by age, before the symptomatic appearance of larger lesions. This high incidence and early onset of tumors is ideal for preclinical studies because mice can be enrolled before symptom onset and with a greater latency period before late-stage disease. Smo/Smo tumors also display leptomeningeal dissemination of neoplastic cells to the brain and spine, which occurs in many human cases. Despite an extended proliferation of granule neuron precursors (GNP) in the postnatal external granular layer (EGL), the internal granular layer formed normally in Smo/Smo mice and tumor formation occurred only in localized foci on the superficial surface of the molecular layer. Thus, tumor formation is not simply the result of over proliferation of GNPs within the EGL. Moreover, Smo/Smo medulloblastomas were transplantable and serially passaged in vivo, demonstrating the aggressiveness of tumor cells and their transformation beyond a hyperplastic state. The Smo/Smo model is the first mouse medulloblastoma model to show leptomeningeal spread. The adherence to human pathology, high incidence, and early onset of tumors thus make Smo/Smo mice an efficient model for preclinical studies.